Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Marinomed Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Last Patient Completes Marinomed Biotech AG\u2019s Phase II Clinical Trial of Tacrosolv to Treat Ocular Hay Fever Symptoms","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"AUSTRIA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Marinomed Biotech"}]

Marinomed Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Last Patient Completes Marinomed Biotech AG’s Phase II Clinical Trial of Tacrosolv to Treat Ocular Hay Fever Symptoms

Details:

Tacrosolv is an improved formulation of tacrolimus, an immunomodulator that can suppress inflammatory reactions, including allergic symptoms. Tacrosolv promises higher bioavailability for local treatment of ocular inflammation.

Lead Product(s): Tacrolimus

Therapeutic Area: Immunology Product Name: Tacrosolv

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 12, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY